ImmunityBio (IBRX) Interest Coverage Ratio Growth (1y) (2017 - 2026)
Powered by 
Analysis
ImmunityBio (IBRX) Interest Coverage Ratio Growth (1y) (2017 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -60.78% |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn | -176.09% |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - | 93.04% |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn | -25.59% |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn | 1,170.12% |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | -53.46% |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn | 99.48% |
| 10 | ImmunityBio | 8.45 Bn | 8.09 Bn | 50.94 Mn | 4.69% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 4.69% |
| Mar 31, 2026 | -13.67% |
| Dec 31, 2025 | -63.39% |
| Sep 30, 2025 | -33.23% |
| Jun 30, 2025 | -38.14% |
| Mar 31, 2025 | -30.20% |
| Dec 31, 2024 | 98.75% |
| Sep 30, 2024 | -19.61% |
| Jun 30, 2024 | -26.25% |
| Mar 31, 2024 | 13.65% |
| Dec 31, 2023 | -7,081.63% |
| Sep 30, 2023 | 57.76% |
| Jun 30, 2023 | 67.83% |
| Mar 31, 2023 | 66.89% |
| Dec 31, 2022 | 83.16% |
| Sep 30, 2022 | 75.17% |
| Jun 30, 2022 | 65.81% |
| Mar 31, 2022 | 58.49% |
| Dec 31, 2021 | -62.12% |
| Sep 30, 2021 | 26.29% |